Monitoring of pathogen resistance profiles is necessary to guide empirical antibiotic therapy before culture and sensitivity results become available. The aim of this study was to describe current antibiotic resistance patterns of five most frequent causative uropathogens in a Department of Urology of a tertiary referral centre in Central Europe over a period of nine years. The Hospital Department of Clinical Microbiology database was used to extract data on all positive urine samples from inpatients in the Department of Urology between 2011 and 2019. Numbers of susceptible and resistant isolates per year were calculated for five most frequent uropathogens: Escherichia coli, Enterococcus spp., Klebsiella spp., Pseudomonas aeruginosa, and Proteus spp. Antimicrobial agents selected for the survey included: ampicillin, amoxicillin/clavulanic acid, piperacillin/tazobactam; cefuroxime, cefotaxime, ceftazidime and cefepime; ciprofloxacin and ofloxacin; gentamicin and amikacin; ertapenem, meropenem and imipenem; trimethoprim-sulfamethoxazole (co-trimoxazole), nitrofurantoin, colistin, and vancomycin. High resistance rates of Gram-negative uropathogens were demonstrated to most common antimicrobials, with statistically significant increasing or decreasing trends in some cases. No carbapenem-resistant Enterobacteriaceae were isolated. Vancomycin-resistant Enterococcus spp. strains were rare in our population.

Department of Clinical Microbiology Thomayer Hospital Videnska 800 140 59 Prague Czech Republic

Department of Urology 3rd Faculty of Medicine Charles University and Thomayer Hospital Videnska 800 140 59 Prague Czech Republic

Zobrazit více v PubMed

Manyi-Loh C., Mamphweli S., Meyer E., Okoh A. Antibiotic use in agriculture and its consequential resistance in environmental sources: Potential public health implications. Molecules. 2018;23:795. doi: 10.3390/molecules23040795. PubMed DOI PMC

Bonkat G., Müller G., Braissant O., Frei R., Tschudin-Suter S., Rieken M., Wyler S., Gasser T.C., Bachmann A., Widmer A.F. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates. World J. Urol. 2013;31:1427–1432. doi: 10.1007/s00345-013-1031-5. PubMed DOI

Iacchini S., Sabbatucci M., Gagliotti C., Rossolini G.M., Moro M.L., Iannazzo S., D’Ancona F., Pezzotti P., Pantosti A. Bloodstream infections due to carbapenemas eproducing Enterobacteriaceae in Italy: Results from nationwide surveillance, 2014 to 2017. Eurosurveillance. 2019;24:1800159. doi: 10.2807/1560-7917.ES.2019.24.5.1800159. PubMed DOI PMC

Cullen I.M., Manecksha R.P., Mccullagh E., Ahmad S., O’Kelly F., Flynn R.J., McDermott T., Murphy P., Grainger R., Fennell J.P., et al. The changing pattern of antimicrobial resistance within 42 033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999–2009. BJUI Int. 2011;109:1198–1206. doi: 10.1111/j.1464-410X.2011.10528.x. PubMed DOI

Lob S.H., Nicolle L.E., Hoban D.J., Kazmierczak K.M., Badal R.E., Sahm D.F. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014. Diagn. Microbiol. Infect. Dis. 2016;85:459–465. doi: 10.1016/j.diagmicrobio.2016.04.022. PubMed DOI

Guyomard-Rabenirina S., The Laboratory Working Group. Malespine J., Ducat C., Sadikalay S., Falord M., Harrois D., Richard V., Dozois C., Breurec S., et al. Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe. BMC Microbiol. 2016;16:121. doi: 10.1186/s12866-016-0749-9. PubMed DOI PMC

Sierra-Díaz E., Hernández-ríos C.J., Bravo-cuellar A. Antibiotic resistance: Microbiological profile of urinary tract infections in Mexico. Cir. Cir. 2019;87:176–182. doi: 10.24875/CIRU.18000494. PubMed DOI

Okeke I.N., Laxminarayan R., Bhutta Z.A., Duse A.G., Jenkins P., O’Brien T.F., Pablos-Mendez A., Klugman K.P. AMR Resistance in developing countries. Lancet Infect. Dis. 2005;5:481–493. doi: 10.1016/S1473-3099(05)70189-4. PubMed DOI

Fasugba O., Mitchell B.G., Mnatzaganian G., Das A., Collignon P., Gardner A. Five-Year Antimicrobial Resistance Patterns of Urinary Escherichia coli at an Australian Tertiary Hospital: Time Series Analyses of Prevalence Data. PLoS ONE. 2016;11:e0164306. doi: 10.1371/journal.pone.0164306. PubMed DOI PMC

Hyun M., Noh C.I., Ryu S.Y., Kim H.A. Changing trends in clinical characteristics and antibiotic susceptibility of Klebsiella pneumoniae bacteremia. Korean J. Intern. Med. 2018;33:595–603. doi: 10.3904/kjim.2015.257. PubMed DOI PMC

Karlowsky J.A., Hoban D.J., Hackel M.A., Lob S.H., Sahm D.F. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013–2015. J. Med. Microbiol. 2017;66:61–69. doi: 10.1099/jmm.0.000421. PubMed DOI

World Health Organization . 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline. WHO; Geneva, Switzerland: 2019. [(accessed on 24 April 2020)]. Available online: https://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/

Frost I., Van Boeckel T.P., Pires J., Craig J., Laxminarayan R. Global geographic trends in antimicrobial resistance: The role of international travel. J. Travel Med. 2019;26:taz036. doi: 10.1093/jtm/taz036. PubMed DOI

Zowawi H.M., Harris P.N.A., Roberts M.J., Tambyah P.A., Schembri M.A., Pezzani M.D., Williamson D.A., Paterson D. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat. Rev. Urol. 2015;12:570–580. doi: 10.1038/nrurol.2015.199. PubMed DOI

Schaeffer A., Schaeffer E. Infections of the urinary tract. In: Wein A., Kavoussi L., editors. Campbell-Walsh Urology. 10th ed. Elsevier Saunders; Philadelphia, PA, USA: 2012. pp. 258–260.

François M., Hanslik T., Dervaux B., Le Strat Y., Souty C., Vaux S., Maugat S., Rondet C., Sarazin M., Heym B., et al. The economic burden of urinary tract infections in women visiting general practices in France: A cross-sectional survey. BMC Health Serv. Res. 2016;16:365. doi: 10.1186/s12913-016-1620-2. PubMed DOI PMC

Vallejo-Torres L., Pujol M., Shaw E., Wiegand I., Vigo J.M., Stoddart M., Grier S., Gibbs J., Vank C., Cuperus N., et al. Cost of hospitalised patients due to complicated urinary tract infections: A retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: The COMBACTE-MAGNET, RESCUING study. BMJ Open. 2018;8:e020251. doi: 10.1136/bmjopen-2017-020251. PubMed DOI PMC

Stapleton P.J., Lundon D.J., McWade R., Scanlon N., Hannan M.M., O’Kelly F., Lynch M. Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005–2014. Ir. J. Med. Sci. 2017;186:733–741. doi: 10.1007/s11845-016-1538-z. PubMed DOI

Klein E.Y., Van Boeckel T.P., Martinez E., Pant S., Gandra S., Levin S.A., Goossens H., Laxminarayan R. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc. Natl. Acad. Sci. USA. 2018;115:E3463–E3470. doi: 10.1073/pnas.1717295115. PubMed DOI PMC

Kandil H., Cramp E., Vaghela T. Trends in Antibiotic Resistance in Urologic Practice. Eur. Urol. Focus. 2016;2:363–373. doi: 10.1016/j.euf.2016.09.006. PubMed DOI

Adriaenssens N., Coenen S., Versporten A., Muller A., Minalu G., Faes C., Vankerckhoven V., Aerts M., Hens N., Molenberghs G., et al. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient antibiotic use in Europe (1997–2009) J. Antimicrob. Chemother. 2011;66:3–12. doi: 10.1093/jac/dkr190. PubMed DOI

Durkin M.J., Keller M., Butler A.M., Kwon J.H., Dubberke E.R., Miller A.C., Polgreen P.M., Olsen M.A. An assessment of inappropriate antibiotic use and guideline adherence for uncomplicated urinary tract infections. Open Forum Infect. Dis. 2018;5:ofy198. doi: 10.1093/ofid/ofy198. PubMed DOI PMC

Fleming-Dutra K., Hersh A.L., Shapiro D.J. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010–2011. JAMA. 2016;315:1865–1873. doi: 10.1001/jama.2016.4151. PubMed DOI

Chardavoyne P.C., Kasmire K.E. Appropriateness of Antibiotic Prescriptions for Urinary Tract Infections. West. J. Emerg. Med. 2020;21:633–639. doi: 10.5811/westjem.2020.1.45944. PubMed DOI PMC

Cai T., Palagin I., Brunelli R., Cipelli R., Pellini E., Truzzi J.C., Van Bruwaene S. Office-based approach to urinary tract infections in 50,000 patients: Results from the REWIND study. Int. J. Antimicrob. Agents. 2020;56:105966. doi: 10.1016/j.ijantimicag.2020.105966. PubMed DOI

Luepke K.H., Luepke K.H., Boucher H., Russo R.L., Bonney M.W., Hunt T.D., Mohr J.F. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2017;37:71–84. doi: 10.1002/phar.1868. PubMed DOI

Theuretzbacher U., Bush K., Harbarth S., Paul M., Rex J.H., Tacconelli E., Thwaites G.E. Critical analysis of antibacterial agents in clinical development. Nat. Rev. Microbiol. 2020;18:286–298. doi: 10.1038/s41579-020-0340-0. PubMed DOI

Theuretzbacher U., Piddock L.J.V. Non-traditional antibacterial therapeutic options and challenges. Cell Host Microbe. 2019;26:61–72. doi: 10.1016/j.chom.2019.06.004. PubMed DOI

Tiwari V., Mishra N., Gadani K., Solanki P.S., Shah N.A., Tiwari M. Mechanism of anti-bacterial activity of zinc oxide nanoparticle against Carbapenem-Resistant Acinetobacter baumannii. Front. Microbiol. 2018;9:1218. doi: 10.3389/fmicb.2018.01218. PubMed DOI PMC

Abdelhamid A.G., Esaam A., Hazaa M.M. Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli. Saudi Pharm. J. 2018;26:603–607. doi: 10.1016/j.jsps.2018.03.004. PubMed DOI PMC

Iseppi R., Di Cerbo A., Aloisi P., Manelli M., Pellesi V., Provenzano C., Camellini S., Messi P., Sabia C. In vitro activity of essential oils against planktonic and biofilm cells of extended-spectrum β-lactamase (ESBL)/carbapenamase-producing gram-negative bacteria involved in human nosocomial infections. Antibiotics. 2020;9:272. doi: 10.3390/antibiotics9050272. PubMed DOI PMC

Sybesma W., Zbinden R., Chanishvili N., Kutateladze M., Chkhotua A., Ujmajuridze A., Mehnert U., Kessler T.M. Bacteriophages as Potential Treatment for Urinary Tract Infections. Front. Microbiol. 2016;7:465. doi: 10.3389/fmicb.2016.00465. PubMed DOI PMC

Magyar A., Koves B., Nagy K., Dobák A., Arthanareeswaran V.K.A., Bálint P., Wagenlehner F., Tenke P. Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary. J. Med. Microbiol. 2017;66:788–797. doi: 10.1099/jmm.0.000498. PubMed DOI

Toner L., Papa N., Aliyu S.H., Dev H., Lawrentschuk N., Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: Incidence and antibiotic susceptibility profile over 9 years. World J. Urol. 2016;34:1031–1037. doi: 10.1007/s00345-015-1718-x. PubMed DOI

Sbiti M., Lahmadi K., Louzi L. Profil épidémiologique des entérobactéries uropathogènes productrices de bêta-lactamases à spectre élargi. Pan Afr. Med. J. 2017;28:29. doi: 10.11604/pamj.2017.28.29.11402. PubMed DOI PMC

Cho Y.H., Jung S.I., Chung H.S., Yu H.S., Hwang E.C., Kim S.-O., Kang T.W., Kwon D.D., Park K. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: Focus on susceptibility to fosfomycin. Int. Urol. Nephrol. 2015;47:1059–1066. doi: 10.1007/s11255-015-1018-9. PubMed DOI

Fajfr M., Louda M., Paterová P., Ryskova L., Pacovský J., Košina J., Žemličková H., Brodak M. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: Data from a unicentric study. BMC Urol. 2017;17:33. doi: 10.1186/s12894-017-0222-6. PubMed DOI PMC

van der Donk C.F.M., Beisser P.S., Hoogkamp-Korstanje J.A.A., Bruggeman C.A., Stobberingh E.E. A 12 year (1998–2009) antibiotic resistance surveillance of Klebsiella pneumoniae collected from intensive care and urology patients in 14 Dutch hospitals. J. Antimicrob. Chemother. 2011;66:855–858. doi: 10.1093/jac/dkq538. PubMed DOI

Gajdács M., Urbán E. Comparative Epidemiology and Resistance Trends of Proteae in Urinary Tract Infections of Inpatients and Outpatients: A 10-Year Retrospective Study. Antibiotics. 2019;8:91. doi: 10.3390/antibiotics8030091. PubMed DOI PMC

Lupo A., Haenni M., Madec J.-Y. Antimicrobial Resistance in Acinetobacter spp. and Pseudomonas spp. Microbiol. Spectr. 2018;6 doi: 10.1128/microbiolspec.ARBA-0007-2017. PubMed DOI PMC

Tolker-Nielsen T.I.M., Brinch U.C., Ragas P.C., Andersen J.B.O., Jacobsen C.S., Molin S. Development and Dynamics of Pseudomonas sp. Biofilms. J. Bacteriol. 2000;182:6482–6489. doi: 10.1128/JB.182.22.6482-6489.2000. PubMed DOI PMC

EMEA Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone and Fluoroquinolone Antibiotics. [(accessed on 12 April 2020)]; Available online: https://www.ema.europa.eu/en/news/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone.

Bonkat G., Wagenlehner F. In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default ? Eur. Urol. 2019;75:205–207. doi: 10.1016/j.eururo.2018.10.057. PubMed DOI

Toner L., Papa N., Aliyu S.H., Dev H., Lawrentschuk N., Al-Hayek S. Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom. Investig. Clin. Urol. 2016;57:129–134. doi: 10.4111/icu.2016.57.2.129. PubMed DOI PMC

Bonkat G., Bartoletti R., Bruyère F., Cai T., Geerlings S., Köves B., Schubert S., Wagenlehner F. Urological Infections. [(accessed on 17 September 2020)];2020 Available online: https://uroweb.org/guideline/urological-infections/

Wagenlehner F.M., Tandoğdu Z., Bartoletti R., Cai T., Cek M., Kulchavenya E.V., Koves B., Naber K., Perepanova T.S., Tenke P., et al. The global prevalence of infections in urology study: A long-term, worldwide surveillance study on urological infections. Pathogens. 2016;5:10. doi: 10.3390/pathogens5010010. PubMed DOI PMC

The Role of Stratified Cumulative Antibiograms in the (Choice of Appropriate Antibiotics in Urinary Tract Infection) Management of Urinary Tract Infections

Current antibiotic resistance patterns of rare uropathogens: survey from Central European Urology Department 2011-2019